Press Releases
Search
-
22 Oct 2015
Information financière du 3e trimestre 2015
Robust growth in nine-month sales: Sales reached €1,412 million Up 18.3% as reported Up 8.3% at constant exchange rates and scope of consolidation Solid momentum in the Americas and EMEA1 regions in t...
-
09 Oct 2015
BioFire Diagnostics receives a de novo clearance by the FDA for the FilmArray® Meningitis/Encephalitis panel continuing its extremely favorable business momentum
FilmArray® expanded menu, with a fourth panel, is the largest available on a molecular biology multiplex platform...
-
24 Sep 2015
BioFire Defense, a bioMérieux company, receives Emergency Use Assessment and Listing for FilmArray® Ebola Test by the World Health Organization
Marcy l’Etoile (France) – September 24, 2015 – BioFire Defense, LLC of Salt Lake City, UT announces that its FilmArray® Ebola test (BioThreat-E test1) has received Emergency Use Assessment and Listing...
-
31 Aug 2015
bioMérieux – First-Half 2015 Results
Strong growth in business €933 million in sales Up 19.5% as reported Up 8.1% like-for-like Sharp 34% improvement in contributive operating income before non-recurring items lifted by strong business m...
-
27 Jul 2015
bioMérieux receives FDA 510(k) clearance for VIDAS® 3, the new generation of VIDAS®
Marcy l'Etoile, France, July 27, 2015 — bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIDAS® 3, the new generation of VIDAS®, received FDA 510(k) clearance. This inst...
-
17 Jul 2015
First-Half 2015 Business Review
Strong growth in business €933 million in sales Up 19.5% as reported Up 8.1% like-for-like Fast-rising sales in the Americas, up 18.3%, and a return to more sustained expansion in the Asia-Pacific, up...
-
22 Jun 2015
Global experts engage in the fight against antimicrobial resistance during the World HAI/Resistance Forum organized by bioMérieux
For the Forum’s 5th edition, bioMérieux commits to support a global educational project on the fight against antimicrobial resistance recognized as a major global public health threat.
-
11 May 2015
2014 Financial Results
Solid growth in sales: Up 8.7%, including BioFire and at constant exchange rates Up 3.8%, at constant exchange rates and scope of consolidation Contributive operating income before non-recurring items...
-
23 Apr 2015
bioMérieux - First-Quarter 2015 Business Review
Strong growth in sales €448 million in sales Up 20.8% as reported Up 8.7% at constant exchange rates and scope of consolidation Sales off to a fast start in the Americas, up 19.6%* Strengthened positi...
-
14 Apr 2015
BioFire dépose auprès de la FDA une demande de novo pour le panel FilmArray® Méningite - Encéphalite
Marcy l’Etoile, France - April 14, 2015 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its molecular biology affiliate, has submitted a de novo classi...
-
26 Feb 2015
BioFire Receives FDA Clearance for the FilmArray® 2.0 System
New system delivers higher throughput, single database management and minimized footprint Marcy l’Etoile, France – February 26, 2015 – bioMérieux, a world leader in the field of in vitro diagnostics, ...
-
10 Feb 2015
BioFire Defense, a bioMérieux Company, Receives Prestigious Frost & Sullivan’s 2014 Global New Product Innovation Award for its FilmArray® Ebola Test
BioFire Defense, LLC is proud to announce that it is the recipient of the Frost & Sullivan’s 2014 Global New Product Innovation Award for its FilmArray® Ebola test. The New Product Innovation Award is...
-
22 Jan 2015
bioMérieux and Astute Medical sign a global agreement to develop and market NephroCheck® Test for VIDAS®, an assay to assess the risk of developing acute kidney injury
Marcy l’Etoile, (France) - San Diego, California (United States) - January 22, 2015 - bioMérieux, a world leader in the field of in vitro diagnostics, and Astute Medical, Inc., a company dedicated to ...
-
22 Jan 2015
Business Review for the Three Months and Full Year Ended December 31, 2014
Sales: solid growth, lifted sharply by BioFire Revenue: €1,698 million, up a reported 7% Up 8.7%, including BioFire and at constant exchange rates Up 3.8% at constant exchange rates and scope of conso...
-
09 Jan 2015
Strategic alliance between bioMérieux and COPAN to automate clinical microbiology laboratories and enhance their operational efficiency
bioMérieux distributes COPAN’s WASP® and WASPLab™ automated systems and speeds up deployment of its “FMLA® - Lab Efficiency” vision »...